The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study

Biomedicine and Pharmacotherapy

Volumn 66, Issue 5, 2012, Pages 348-353

  Bonfanti, Paolo ^a   De Socio, Giuseppe Vittorio ^b   Ricci, Elena ^c   Antinori, Andrea ^d   Martinelli, Canio ^e   Vichi, Francesca ^f   Penco, Giovanni ^g   Madeddu, Giordano ^h   Orofino, Giancarlo ⁱ   Valsecchi, Laura ^c   Rusconi, Stefano ^j   Menzaghi, Barbara ^k   Pocaterra, Daria ^c   Quirino, Tiziana ^k  

^a A MANZONI HOSPITAL   (Italy)

^b Santa Maria Hospital   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^g GALLIERA HOSPITAL   (Italy)

^h UNIVERSITY OF SASSARI   (Italy)

ⁱ AMEDEO DI SAVOIA HOSPITAL   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

^k BUSTO ARSIZIO HOSPITAL   (Italy)

more..

Author keywords

Antiretroviral therapy; Cardiovascular risk; HIV; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84863992327     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.01.005     Document Type: Article

References (33)

1. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
2. Jericò C., Knobel H., Montero M., et al. Metabolic Syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132-137.
3. Jacobson D.L., Tang A.M., Spiegelman D., et al. Incidence of MS in a cohort of HIV-infected adults and prevalence relative to the US population. J Acquir Immune Defic Syndr 2006, 43:458-466.
4. Wand H., Calmy A., Carey D.L., et al. INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453.
5. Mondy K., Overton E.T., Grubb J., et al. Metabolic syndrome in HIV-infected patients from an urban. Midwestern US outpatient population. Clin Infect Dis 2007, 44:726-734.
6. Mangili A., Jacobson D.L., Gerrior J., Polak J.F., Gorbach S.L., Wanke C.A. Metabolic syndrome and sub clinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007, 44:1368-1374.
7. Worm S.W., Lundgren J.D. The Metabolic Syndrome in HIV. Best Pract Res Clin Endocrinol Metab 2011, 25:479-486.
8. De Socio G.V., Parruti G., Quirino T., For the CISAI study group, et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008, 57:33-40.
9. Bonfanti P., De Socio G.V.L., Marconi P., et al. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res 2010, 8(2):165-171.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
11. De Socio G.V.L., Martinelli C., Ricci E., For the HERMES study group, et al. Relations between cardiovascular risk estimates and sub clinical atherosclerosis in naive HIV patients: results from the HERMES Study. Int J STD AIDS 2010, 21:267-272.
12. Palacios R., Santos J., González M., Ruiz J., Márquez M. Incidence prevalence of the metabolic syndrome in a cohort of naïve HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS 2007, 18:184-187.
13. Bergersen B.M., Schumacher A., Sandvik L., Bruun J.N., Birkeland K. Important differences in components of the metabolic syndrome between HIV patients with and without highly active antiretroviral therapy, and healthy controls. Scand J Infect Dis 2006, 38:682-689.
14. Samaras K., Wand H., Law M., et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and corrected hypoadiponectinemia. Diab Care 2007, 30:113-119.
15. Falasca K., Ucciferri C., Manzoli L., et al. Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol 2007, 20:519-527.
16. Jevtovic D.J., Dragovic G., Salemovic D., Ranin J., Djurkovic-Djakovic O. The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomed Pharmacother 2009, 63:337-342.
17. Bonfanti P., Giannattasio C., Ricci E., et al. HIV and Metabolic Syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007, 45:426-431.
18. Sobieszczyk M.E., Hoover D.R., Anastos K., et al. Prevalence and predictors of metabolic syndrome among HIV-Infected and HIV-Uninfected women in the Women's Interagency HIV study. J AIDS 2008, 48:272-280.
19. Baum M.K., Rafie C., Lai S., et al. Coronary heart disease (CHD) risk factors and metabolic syndrome in HIV-positive drug users in Miami. Am J Infect Dis 2006, 2:173-179.
20. Hansen B.R., Petersen J., Haugaard S.B., et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Medications 2009, 10:378-387.
21. Fontas E., van Leth F., Sabin C.A., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Diseases 2004, 189:1056-1074.
22. Leon A., Martinez E., Sarasa M., et al. Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues. JAntimicr Chemother 2007, 60:824-830.
23. van Leth F., Phanuphak P., Stroes E., et al. Nevirapine and efavirenz elicit different changes in lipid profiles in anti-retroviral therapy-naive patients infected with HIV-1. PLoS Medicine 2004, 1:19.
24. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
25. Noor M.A., Lo J.C., Mulligan K., et al. Metabolic effects of indinavir in healthy HIV-seronegative men. Acquired Immune Deficiency Syndrome 2001, 15:F11-F18.
26. Lee G.A., Seneviratne T., Noor M.A., et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. Acquired Immune Deficiency Syndrome 2004, 18:641-649.
27. Franssen R., Sankatsing R.R., Hassink E., et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 2009, 29:1336-1341.
28. Phillips A.N., Carr A., Neuhaus J., et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Therapy 2008, 13:177-187.
29. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978-2982.
30. El-Sadr W.M., Mullin C.M., Carr A., et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naïve cohort. HIV Med 2005, 6:114-121.
31. Baker J.V., Neuhaus J., Duprez D., et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011, 25:2133-2142.
32. Norata G.D., Pirillo A., Ammirati E., Catapano A.L. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2011, 10.1016/j.atherosclerosis.2011.06.045.
33. Mujawar Z., Rose H., Morrow M.P., Pushkarsky T., Dubrovsky L., Mukhamedova N., et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006, 4:e365.